PEAK6 Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

PEAK6 Group’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$88K	Sell	1,163 -5,281	-82%	-$332K	﹤0.01%	3750
2018 Q1	$340K	Buy	+6,444	New	+$375K	﹤0.01%	2948
2016 Q3	–	Sell	-9,000	Closed	-$349K	–	4810
2016 Q2	$349K	Buy	9,000 +500	+6%	+$20.8K	﹤0.01%	2689
2016 Q1	$344K	Buy	+8,500	New	+$539K	﹤0.01%	2635
2015 Q3	–	Sell	-300	Closed	-$24K	–	5690
2015 Q2	$24K	Buy	+300	New	+$19.5K	﹤0.01%	4759

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

PEAK6 Group's EGRX Position: Q2 2018 in Review

PEAK6 Group reduced its Eagle Pharmaceuticals, Inc. (EGRX) stake by 82% in Q2 2018, selling an estimated $332K and leaving 1,163 shares worth $88K. The position accounts for ﹤0.01% of the portfolio, ranked #3750.

PEAK6 Group first reported a position in EGRX in Q2 2015 and has held it in 5 quarters since. The position peaked at $349K in Q2 2016. 183 funds tracked by Wall St. Rank hold EGRX as of Q2 2018.

PEAK6 Group held 1,163 shares of Eagle Pharmaceuticals, Inc. worth $88K as of Q2 2018.
PEAK6 Group sold 5,281 Eagle Pharmaceuticals, Inc. shares in Q2 2018, an estimated $332K.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of PEAK6 Group's portfolio in Q2 2018, its #3750 holding.
PEAK6 Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and has held it in 5 quarters since.
PEAK6 Group's Eagle Pharmaceuticals, Inc. position peaked at $349K in Q2 2016.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.